Clinical Trial Update: Doxil/Caelyx BE Study [Phase 1]

View source ↗

Summary

Phase 1 bioequivalence study completion for Doxil/Caelyx in ovarian cancer, Kaposi sarcoma, multiple myeloma, and metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Kaposi Sarcoma
• Multiple Myeloma
• Ovarian Cancer

Drugs mentioned

• Doxil/Caelyx (liposomal doxorubicin)

Snippet

Sponsor: Baxter Healthcare Corporation | Conditions: Ovarian Cancer, AIDS-related Kaposi Sarcoma | Phase 1 | Status: COMPLETED